Sometimes, a single worry grows so large that it obscures all the good things happening at the same time. That’s the case with the stock of pharma giant
AbbVie
whose blockbuster drug Humira faces patent expirations.
Humira is an immunosuppressive that’s racked up nearly $200 billion in sales since its 2002 approval. AbbVie (ticker: ABBV) has fought fiercely to extend its exclusivity of Humira, which treats conditions from rheumatoid arthritis to Crohn’s disease, but it has already lost patent protection in Europe and faces increased competition from biosimilars in the U.S., beginning next year.